Data Monitoring Committee (DMC) has performed another, scheduled review of the CHF trial data and recommended continuation of the trial without modification. Enrollment of this Phase 3 trial is expected to be completed by the end of 2018.
LVAD National Institutes for Health (NIH) Phase 2 trial has also completed enrollment with 12-month data read-out expected in the next quarter (Q3 CY18). Mesoblast is actively pursuing a potential accelerated entry pathway for MPC-150-IM into the cardiovascular market that may be provided by RMAT designation.
So, my take on this is both of these Tier 1 trials are confirmed on track with results coming in expected time-frames.
- Forums
- ASX - By Stock
- MSB
- Ann: MSB Clinical Program Update For MPC-150-IM In Heart Failure
Ann: MSB Clinical Program Update For MPC-150-IM In Heart Failure, page-2
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.67 |
Change
0.003(0.15%) |
Mkt cap ! $293.1M |
Open | High | Low | Value | Volume |
$1.66 | $1.72 | $1.66 | $7.790M | 4.648M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
35 | 85086 | $1.67 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.68 | 33868 | 12 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2 | 1.375 |
1 | 82 | 1.370 |
1 | 3981 | 1.365 |
7 | 49392 | 1.360 |
1 | 4134 | 1.355 |
Price($) | Vol. | No. |
---|---|---|
1.385 | 247 | 1 |
1.400 | 4328 | 1 |
1.405 | 12000 | 2 |
1.410 | 18724 | 1 |
1.420 | 12000 | 2 |
Last trade - 14.19pm 06/12/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |